

DATA SUPPLEMENT

Table DS1 Clinical and record profile of individuals started on depot antipsychotics							
	Risperidone long-acting injection (n = 122)	Zuclopendithoxol decanoate (n = 31)	Flupenthixol decanoate (n = 43)	Fluphenazine decanoate (n = 11)	Pipothiazine palmitate (n = 7)	Haloperidol decanoate (n = 3)	P ^a
Age, years: mean (95% CI)	39.0 (36.9–41.0)	39.0 (34.3–43.6)	40.1 (37.1–44.5)	37.3 (28.7–45.9)	40.4 (26.0–54.8)	44.9 (6.8–83.0)	NS
Duration of contact with mental health services prior to depot							NS
0–1 year, n	5	4	1	1	1	0	
1–3 years, n	8	3	2	0	0	0	
>3 years, n (%)	109 (89)	24 (77)	40 (93)	10 (91)	6 (86)	3 (100)	
Male, n (%)	76 (62)	16 (52)	25 (58)	9 (82)	6 (86)	3 (100)	NS
Compulsory treatment, n (%)	28 (23)	10 (32)	6 (14)	4 (36)	2 (29)	2 (67)	NS
History of alcohol misuse, n (%)	57 (47)	13 (42)	19 (44)	5 (45)	4 (57)	0 (0)	NS
History of substance misuse, n (%)	41 (34)	12 (39)	13 (30)	7 (64)	2 (29)	1 (33)	NS
Diagnosis of schizoaffective disorder, n (%)	23 (19)	8 (26)	7 (16)	2 (18)	0 (0)	0 (0)	NS
Previously on oral or intramuscular antipsychotics (i.e. those 'switching' medications), n (%)	112 (92)	25 (81)	37 (86)	8 (73)	6 (86)	3 (100)	NS
Previously on depot antipsychotics (i.e. those 'switching' from another depot), n (%)	28 (23)	6 (19)	11 (26)	1 (9)	6 (86)	1 (33)	NS
Reason given for discontinuing previous antipsychotic, n (%)							
Inefficacy	48 (39)	19 (61)	21 (49)	5 (45)	3 (43)	2 (67)	0.052 ^b
Side-effects	14 (11)	2 (6)	4 (9)	0 (0)	1 (14)	0 (0)	
Non-adherence	48 (39)	5 (16)	9 (21)	3 (27)	0 (0)	1 (33)	
Maximum dose, median mg/14 days equivalent (range)	37.5 (25.0–50.0)	400 (100–1200)	60 (20–250)	25 (25–100)	37.5 (25–75)	200 (75–200)	
Regular additional oral antipsychotic, n (%)	30 (25)	9 (29)	17 (40)	3 (27)	2 (28)	2 (67)	NS
Regular additional oral antipsychotic dose, per cent of BNF maximum, median (range)	25 (6–130)	35 (25–100)	30 (10–55)	67 (33–67)	75 (50–75)	79 (50–108)	NS
Co-prescription (antidepressant), n (%)	46 (38)	13 (42)	22 (51)	4 (36)	2 (28)	1 (33)	NS
Co-prescription (mood stabiliser), n (%)	14 (11)	5 (16)	3 (7)	1 (9)	1 (14)	1 (33)	NS
Clozapine considered or tried (before/after depot), n (%)	30 (25)	3 (10)	8 (19)	5 (45)	2 (28)	1 (33)	NS
Total patient-years of depot treatment	166.4	44.2	48.8	6.7	10.5	7.0	
Record before depot started, months: mean (95% CI)	16.8 (14.3–19.2)	18.5 (12.3–24.6)	15.6 (10.4–20.7)	18.7 (14.3–32.2)	23.3 (7.0–39.6)	5.9 (6.3–18.4)	NS
Duration of record, months: mean (95% CI)	47.0 (44.0–49.9)	38.8 (32.4–45.1)	47.0 (40.9–53.0)	58.2 (42.6–73.8)	46.2 (20.7–71.7)	33.9 (5.6–62.1)	0.054 ^c
Duration of depot treatment, months: mean (95% CI)	16.5 (14.0–19.0)	17.1 (12.5–21.7)	13.6 (9.8–17.5)				NS
District that records came from, n (%)							NS
Motherwell/Clydesdale	93 (76)	18 (58)	29 (67)				
Hairmyres/East Kilbride	16 (13)	5 (16)	7 (16)				
Monklands	13 (11)	8 (26)	7 (16)				

NS, not significant; BNF, British National Formulary.

a. Risperidone long-acting injection v. zuclopendithoxol decanoate v. flupenthixol decanoate.

b. $\chi^2 = 9.39$, d.f. = 4.

c. $F(2,193) = 2.97$. Difference between risperidone long-acting injection v. zuclopendithoxol, $P = 0.04$.